分红方面，理邦仪器A股上市后累计派现11.28亿元。近三年，累计派现3.60亿元。 机构持仓方面，截止2025年9月30日，理邦仪器十大流通股东中，香港中央结算有限公司位居第一大流 通股东，持股3386.87万股，相比上期减少309.93万股。医疗器械ETF（159883）位居第九大流通股东， 持股178.76万股，为新进股东。博道远航混合A（007126）位居第十大流通股东，持股167.37万股，为 新进股东。招商量化精选股票发起式A（001917）退出十大流通股东之列。 理邦仪器所属申万行业为：医药生物-医疗器械-医疗设备。所属概念板块包括：互联医疗、小盘、多胎 概念、养老产业、医疗器械等。 截至11月10日，理邦仪器股东户数2.35万，较上期减少3.61%；人均流通股14407股，较上期增加 3.74%。2025年1月-9月，理邦仪器实现营业收入14.46亿元，同比增长4.63%；归母净利润2.57亿元，同 比增长49.29%。 11月27日，理邦仪器盘中上涨2.04%，截至13:03，报14.01元/股，成交7579.30万元，换手率1.63%，总 市值81.21亿元。 资金流向方面，主力资金净流入5 ...

Financial Performance - In Q1 2025, the company achieved a revenue of 420 million CNY, a decrease of approximately 5% year-on-year [3] - Domestic sales revenue was 166 million CNY, down about 20% year-on-year, while international sales revenue was 254 million CNY, up approximately 7% [3] - The overall gross margin for 2024 reached 57.92%, showing an improvement due to an increase in high-margin product sales [8] Market Outlook - The company maintains an optimistic outlook for domestic sales growth in 2025, anticipating recovery in market demand and the introduction of competitive new products [3] - The overseas patient monitoring business is expected to grow at a double-digit rate, with positive performance in Q1 2025 [11] AI Integration - The company established an AI-focused organization in March 2025, aiming to enhance efficiency and create value in ultrasound imaging and smart healthcare [4] - AI applications have significantly reduced examination times and improved patient flow management in emergency settings [4] Supply Chain and Tariff Impact - Components imported from the U.S. account for approximately 0-10% of the main product costs, with ongoing adjustments to ensure supply chain stability amid tariff uncertainties [9] - The company has initiated capacity expansion for its U.S. subsidiary to mitigate the impact of increased tariffs, with completion expected by June 2025 [7] Product Development and Strategy - The i500 wet blood gas product has been cautiously promoted since Q4 2024, with a focus on long-term market leadership and customer satisfaction [12] - The company is actively monitoring the impact of price reductions in IVD products due to centralized procurement policies, which have limited effects on its business [14] Inventory Management - By the second half of 2024, domestic channel inventory levels have returned to normal, allowing for a more stable sales environment [13] - The company has optimized its internal sales team to enhance competitiveness in the domestic market [7] Health Care Product Promotion - The domestic market strategy for personal health care products includes leveraging e-commerce platforms and extending the company's strong brand influence in obstetrics [15]